Literature DB >> 7954868

Clinical and therapeutic aspects of AA amyloidosis.

B P Hazenberg1, M H van Rijswijk.   

Abstract

Approach to the management of AA amyloidosis complicating RA. (A) In case of proteinuria or loss of renal function a rectal biopsy or a subcutaneous fat biopsy is a suitable screening method for the detection of amyloidosis. If in any doubt, try to ascertain the diagnosis by renal biopsy. Adequate staining with alkaline Congo red and preferably immunohistochemical staining with anti-AA antibodies should be performed. Beware of renal pathology other than amyloidosis even in the presence of a positive rectal biopsy. (B) A vigorous attempt to control disease activity of the RA should be made in order to eliminate the production of SAA, an acute phase protein. The response to treatment should be monitored by serial measurements of CRP and preferably SAA. (C) The function of some vital organs should be evaluated: (a) endogenous creatinine clearance and the extent of proteinuria; (b) electrocardiogram and optional echocardiography; (c) thyroid function and adrenocortical function; (d) intestinal absorption tests; (e) optional--SAP scintigraphy and turnover studies. (D) Attention should be given to adequate supportive treatment: (a) blood pressure control; (b) treatment of intercurrent infections; (c) corticosteroids during major surgical procedures; (d) pay attention to the possible effect of NSAID on proteinuria and renal function. (E) In case of total renal failure or uncontrollable proteinuria: (a) consider the possibility of primary renal transplantation; (b) otherwise regular haemodialysis is indicated.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7954868     DOI: 10.1016/s0950-3579(05)80121-9

Source DB:  PubMed          Journal:  Baillieres Clin Rheumatol        ISSN: 0950-3579


  14 in total

1.  [Amyloid diagnostics in rheumatic diseases].

Authors:  C Röcken; J Ernst
Journal:  Pathologe       Date:  2006-11       Impact factor: 1.011

2.  Efficacy and safety of adalimumab in a patient with ankylosing spondylitis on peritoneal dialysis.

Authors:  Senol Kobak
Journal:  Rheumatol Int       Date:  2010-03-26       Impact factor: 2.631

3.  Intractable diarrhoea associated with secondary amyloidosis in rheumatoid arthritis.

Authors:  Y Okuda; K Takasugi; T Oyama; H Oyama; S Nanba; T Miyamoto
Journal:  Ann Rheum Dis       Date:  1997-09       Impact factor: 19.103

Review 4.  Pulmonary, renal and neurological comorbidities in patients with ankylosing spondylitis; implications for clinical practice.

Authors:  Cecilia Mercieca; Irene E van der Horst-Bruinsma; Andrew A Borg
Journal:  Curr Rheumatol Rep       Date:  2014-08       Impact factor: 4.592

5.  99mTc-HSA-D scintigraphy in the diagnosis of protein-losing gastroenteropathy due to secondary amyloidosis.

Authors:  C Suzuki; S Higaki; M Nishiaki; N Mitani; H Yanai; M Tada; K Okita
Journal:  J Gastroenterol       Date:  1997-02       Impact factor: 7.527

6.  A case of systemic amyloidosis associated with cyclic neutropenia.

Authors:  HyunKyung Lee; Kyoung Hee Han; Yun Hye Jung; Hee Gyung Kang; Kyung Chul Moon; Il Soo Ha; Yong Choi; Hae Il Cheong
Journal:  Pediatr Nephrol       Date:  2010-12-15       Impact factor: 3.714

7.  Renal AA amyloidosis: survey of epidemiologic and laboratory data from one nephrology centre.

Authors:  Z Potysová; M Merta; V Tesar; E Jancová; E Honsová; R Rysavá
Journal:  Int Urol Nephrol       Date:  2009-01-31       Impact factor: 2.370

8.  Prognosis of clinical renal disease and incidence of new renal findings in patients with rheumatoid arthritis: follow-up of a population-based study.

Authors:  K Karstila; M Korpela; S Sihvonen; J Mustonen
Journal:  Clin Rheumatol       Date:  2007-05-10       Impact factor: 2.980

9.  Ankylosing spondylitis-related secondary amyloidosis responded well to etanercept: a report of three patients.

Authors:  Senol Kobak; Fahrettin Oksel; Yasemin Kabasakal; Eker Doganavsargil
Journal:  Clin Rheumatol       Date:  2007-07-05       Impact factor: 2.980

10.  Amyloid A amyloidosis: frequently neglected renal disease in injecting drug users.

Authors:  Ali Nayer
Journal:  J Nephropathol       Date:  2013-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.